Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary Endpoint Is Overall Survival & PFS.
KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary Endpoint Is Overall Survival & PFS
